Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.

Plain Language Summary

Perspective review discussing the rapid growth of GLP-1 RA prescribing (semaglutide, tirzepatide) for obesity alongside emerging concerns about side effects, long-term outcomes, and unregulated compounded products. Advocates for coordinated clinical oversight, pharmacovigilance, and patient monitoring frameworks. Provides a balanced contemporary view on the semaglutide prescribing boom—addressing the gap between enthusiasm driven by efficacy and the need for structured safety monitoring, patient selection rigor, and regulation of the compounded drug market.